Location History:
- Tübingen, DE (2020 - 2022)
- Tuebingen, DE (2020 - 2024)
Company Filing History:
Years Active: 2020-2025
Title: Leonie Alten: Innovating Immunotherapy in Cancer Treatment
Introduction
Leonie Alten, based in Tuebingen, DE, is a prominent inventor within the field of biotechnology, particularly recognized for his substantial contributions to cancer immunotherapy. With a remarkable portfolio of 26 patents, Alten is at the forefront of innovations aimed at enhancing the immune system’s ability to target and destroy cancer cells.
Latest Patents
Among his latest patents are groundbreaking developments in T cell receptors and their applications in immune therapy. One notable invention pertains to antigen recognizing constructs against tumor-associated antigens (MAGEA1). This invention introduces novel T cell receptor (TCR) based molecules that are both selective and specific for tumor-expressed antigens, offering new avenues for the diagnosis, treatment, and prevention of cancerous diseases linked to TAA expression. Additionally, he has disclosed TCRs binding to tumor-associated antigens (TAAs) that assist in targeting cancer cells effectively. These patents extend to various elements such as nucleic acids, vectors, and pharmaceutical compositions that facilitate immunotherapy against cancers.
Career Highlights
Leonie Alten is currently associated with Immatics Biotechnologies GmbH, a company dedicated to pioneering advancements in cancer immunotherapy through innovative biotechnological solutions. His work is recognized for its potential to transform treatment methodologies and improve clinical outcomes for cancer patients.
Collaborations
In his professional journey, Alten collaborates closely with colleagues such as Sebastian Bunk and Dominik Maurer. Their collective expertise contributes to the development of T-cells, T-cell receptors, and various immunotherapeutic methods essential for furthering cancer research and treatment options.
Conclusion
Leonie Alten exemplifies the spirit of innovation essential in the fight against cancer. Through his patents and collaborative efforts at Immatics Biotechnologies GmbH, he continues to explore and develop new therapeutic strategies that harness the power of the immune system, providing hope for patients battling cancer.